ConforMIS Inc (NASDAQ:CFMS) – Analysts at Oppenheimer raised their FY2018 earnings estimates for ConforMIS in a research note issued to investors on Thursday. Oppenheimer analyst S. Lichtman now expects that the medical instruments supplier will earn ($0.82) per share for the year, up from their prior estimate of ($1.01). Oppenheimer currently has a “Buy” rating and a $4.00 target price on the stock.

Other analysts also recently issued research reports about the stock. BTIG Research raised shares of ConforMIS from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Wednesday, December 20th. Zacks Investment Research raised shares of ConforMIS from a “sell” rating to a “hold” rating in a research report on Monday. Canaccord Genuity reduced their price objective on shares of ConforMIS from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Thursday, February 8th. Finally, JPMorgan Chase & Co. downgraded shares of ConforMIS from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 2nd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $4.88.

Shares of ConforMIS (CFMS) traded down $0.03 during mid-day trading on Monday, hitting $1.46. 351,500 shares of the stock traded hands, compared to its average volume of 865,378. The firm has a market cap of $87.70, a P/E ratio of -1.18 and a beta of 1.41. ConforMIS has a one year low of $1.15 and a one year high of $8.61. The company has a current ratio of 6.19, a quick ratio of 5.38 and a debt-to-equity ratio of 0.52.

ConforMIS (NASDAQ:CFMS) last announced its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.03. The company had revenue of $20.80 million during the quarter, compared to the consensus estimate of $20.07 million. ConforMIS had a negative net margin of 68.59% and a negative return on equity of 78.44%. The company’s quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.37) EPS.

In other ConforMIS news, CEO Mark A. Augusti sold 16,548 shares of ConforMIS stock in a transaction on Tuesday, December 19th. The shares were sold at an average price of $2.27, for a total transaction of $37,563.96. Following the transaction, the chief executive officer now directly owns 285,007 shares of the company’s stock, valued at approximately $646,965.89. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 43,691 shares of company stock valued at $91,154. 9.55% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of CFMS. Stonebridge Capital Management Inc. bought a new stake in shares of ConforMIS during the 3rd quarter worth $130,000. The Manufacturers Life Insurance Company raised its stake in shares of ConforMIS by 21.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 6,535 shares during the period. Alliancebernstein L.P. raised its stake in shares of ConforMIS by 31.1% during the 2nd quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 9,500 shares during the period. Rhumbline Advisers raised its stake in shares of ConforMIS by 21.8% during the 2nd quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock worth $192,000 after purchasing an additional 8,017 shares during the period. Finally, Swiss National Bank raised its stake in shares of ConforMIS by 59.2% during the 2nd quarter. Swiss National Bank now owns 53,500 shares of the medical instruments supplier’s stock worth $230,000 after purchasing an additional 19,900 shares during the period. 26.99% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “FY2018 EPS Estimates for ConforMIS Inc (CFMS) Boosted by Oppenheimer” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2018/02/14/fy2018-eps-estimates-for-conformis-inc-cfms-boosted-by-oppenheimer.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Earnings History and Estimates for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.